Marker Therapeutics, Inc.

Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.

MRKR | NDAQ

Overview

Corporate Details

ISIN(s):: US57055L1070 (+1 more)
LEI:
Country:: United States of America
Address:: 2450 HOLCOMBE BLVD, 77021 HOUSTON
Website:: https://markertherapeutics.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation, non-genetically modified T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology, Multi-Antigen Recognizing (MAR) T cells, expands a patient's natural T cells to recognize and eliminate tumors expressing multiple antigens. This approach aims to provide durable anti-tumor responses with a favorable safety profile compared to genetically engineered cell therapies. The technology was developed at Baylor College of Medicine. Its lead product candidate, MT-601, is being evaluated in a Phase 1 study for lymphoma patients who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Marker Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Marker Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Marker Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
BridgeBio Pharma, Inc. Develops transformative medicines for genetic diseases and genetically driven cancers.	United States of America	BBIO
BRIGHT MINDS BIOSCIENCES INC. Developing next-gen serotonergic drugs for neurological and psychiatric disorders like epilepsy.	United States of America	DRUG
BRISTOL MYERS SQUIBB CO Develops innovative medicines for oncology, immunology, and cardiovascular diseases.	United States of America	BMY
BUKWANG PHARMACEUTICAL IND CO.,LTD R&D pharma firm developing drugs for CNS disorders, oncology, and metabolic diseases.	South Korea	003000
Burning Rock Biotech Ltd Offers NGS-based diagnostics for precision oncology, from detection to clinical trial support.	United States of America	BNR
C4 Therapeutics, Inc. Developing protein degrader medicines to treat cancer and other serious diseases.	United States of America	CCCC
Cabaletta Bio, Inc. Develops engineered T cell therapies for a curative reset in autoimmune diseases.	United States of America	CABA
Cadrenal Therapeutics, Inc. Developing novel anticoagulant therapies for high-risk cardiovascular patients.	United States of America	CVKD
CalciMedica, Inc. Develops CRAC channel inhibitors for critical illnesses like acute pancreatitis & AKI.	United States of America	CALC
Calidi Biotherapeutics, Inc. Develops immunotherapies using stem cells to deliver oncolytic viruses against solid tumors.	United States of America	CLDI